Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

The personalised cancer drug is based on the same technology as the leading coronavirus vaccines that helped end the pandemic ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Infinitopes, a clinical-stage cancer vaccine biotechnology company, today announced the successful completion of the second close of its seed financing round, securing an additional $15.4 million and ...

One large study found that more advanced cases of colorectal cancer had a higher likelihood of returning. For example, if participants had stage 3 colon cancer, almost 25 percent experienced a ...

New research reveals that certain brain tumors may originate silently within normal brain cells long before a tumor forms.

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...